News & Events

Redbiotec AG (“Redbiotec” or “the Company”), the leader in protein complexes and designer virus-like particles (VLP), today announces two new appointments to its Scientific Advisory Board. Professor Polly Roy, one of the world’s leading baculovirus specialists, and Professor Rainer Fischer, an expert in molecular immunology and molecular biotechnology, bring extensive experience and knowledge in protein engineering and in VLP-based vaccine approaches.

V+ GmbH & Co Fonds 2 KG, a German Venture Capital fund invests in Redbiotec. The investment strengthens the leading position of Redbiotec in designer virus-like particles (VLPs) and protein complexes. Solidly financed, Redbiotec is applying its unique CAP ® technology for the development of additional novel vaccine and biologic candidates.

On the occasion of BioEurope 2009 in Vienna, Europe’s most important Pharma and Biotech partnering conference, Redbiotec presented its proprietary and cutting-edge protein expression technologies to the international community. Important contacts were established with leading Pharma and Biotech companies. Redbiotec is now in advanced negotiations with several of these regarding the use of its technologies for vaccine development and drug discovery. Redbiotec will also be present at the follow-on conference, BioEurope Spring 2010, in Barcelona.

In Q4 2009 Redbiotec demonstrated a specific immune response of its nature-like influenza virus-like particles in mice. The particles represent an ideal vaccine candidate as they contain all major virus antigens in one virus-like particle.

Redbiotec has successfully implemented novel disposable production technologies into its leading technology platform. These technologies garantee process efficiency with high scalability.